{"analyses":[{"ciLowerLimit":"2.64","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"8.84","estimateComment":"odds ratio \\>1.0 favours Osimertinib 80 mg","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"<0.001","paramType":"Odds Ratio (OR)","paramValue":"4.76","statisticalMethod":"Regression, Logistic"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.3","upperLimit":"11.6","value":"93.2"},{"groupId":"OG001","lowerLimit":"3.0","upperLimit":"5.6","value":"74.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"279"},{"groupId":"OG001","value":"140"}],"units":"Participants"}],"description":"Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) assessed by MRI or CT: Complete Response (CR): Disappearance of all target and non-target lesions and no new lesions; Partial Response (PR): \\>= 30% decrease in the sum of diameters of Target Lesions (compared to baseline) and no new lesions; Stable disease (SD): Neither sufficient shrinkage to qualify as a response nor sufficient growth to qualify as progression; Progressive Disease (PD): \\>= 20% increase in the sum of diameters of TLs and an absolute increase in sum of diameters of \\>=5mm (compared to the previous minimum sum) or progression of NTLs or a new lesion. DCR is the percentage of patients with best response of CR, PR or SD at \\>=6 weeks, prior to any progressive disease (PD).","groups":[{"description":"Daily single dose of Osimertinib 80mg","id":"OG000","title":"Osimertinib 80mg"},{"description":"Platinum-based doublet chemotherapy","id":"OG001","title":"Chemotherapy"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set (All randomised patients)","reportingStatus":"POSTED","timeFrame":"RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).","title":"Disease Control Rate (DCR) by Investigator Assessment","type":"SECONDARY","unitOfMeasure":"% of participants"}